Sign in

    Anna Lee • Truist

    There is no verifiable public information available confirming the existence of Anna Lee as an analyst at Truist, nor any details regarding her job title, specific company coverage, performance metrics, career timeline, or professional credentials. Despite a thorough search, no LinkedIn profile or reputable financial database entry was found for an Anna Lee in an analyst role at Truist. Accordingly, it is not possible to provide a professional profile consistent with the requested details.

    Anna Lee's questions to Curis Inc (CRIS) leadership

    Anna Lee's questions to Curis Inc (CRIS) leadership • Q2 2025

    Question

    Anna Lee from Truist inquired if recent FDA changes have impacted accelerated approval plans for PCNSL, asked for an update on business development efforts given the cash runway, and questioned broader oncology trends affecting Curis.

    Answer

    CDO Jonathan Zung stated that alignment with the FDA remains unchanged. CEO James Dentzer acknowledged industry-wide FDA uncertainty but felt confident due to PCNSL having no approved drugs. CFO Diantha Duvall confirmed the cash runway extends into 2026 and the company is actively evaluating financing opportunities.

    Ask Fintool Equity Research AI